New Delhi, Feb 19: Yoga guru Baba Ramdev's Patanjali Ayurved on Friday said its Coronil tablet has received certification from the Ayush Ministry as a medicine supporting COVID-19 treatment as per the World Health Organization's certification scheme.

Patanjali also released what it claimed was research work supporting Coronil's efficacy in COVID-19 treatment.

The Union Ayush Ministry had earlier categorised ayurvedic Coronil tablets as an ''Immuno-booster''.

Now, it has been recognised as a medicine for "supporting measure in COVID-19" treatment, Ramdev told reporters at a press conference here.

"Study on the impact of Coronil on COVID has already been published in leading journals," Ramdev said, adding "it would work not only for treatment, prevention and cure of COVID but also help in after-effects."

This is the first company in India which has received such a licence, he claimed.

The announcement regarding the Ayush certification for Coronil and release of a research paper calling it the "first evidence-based medicine for COVID-19 by Patanjali" was done at an event here attended by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari.

In a statement, Patanjali said: "Coronil has received the Certificate of Pharmaceutical Product (CoPP) from the Ayush section of Central Drugs Standard Control Organisation as per the WHO certification scheme."

Under CoPP, Coronil can now be exported to 158 countries, it claimed.

Patanjali had introduced ayurveda-based Coronil on June 23 last year, when the pandemic was at its peak. It had to face severe criticism as it lacked scientific evidence regarding its efficacy.

The Ayush Ministry had classified it as an "Immuno-booster" only.

The ministry earlier this month recognised Coronil as a medicine for "supporting measure in COVID-19" treatment, Ramdev said.

"This certification will remove the misconception about it in people''s mind as it cures COVID also," Ramdev said, adding "it will work against asymptomatic, symptomatic and severe (cases) also. We have data for that."

"It received a huge response despite all controversies. We have data which suggests that more than one crore people have consumed it," he added.

Ramdev further said Coronil will help humanity while providing sustainable and affordable treatment.

"Some people manufacture medicines for their business but we have done it for treatment and welfare of the public (upchar aur upkar ke bhavna se)," he said.

After Coronil, Patanjali now plans to introduce more ayurvedic medicines, backed with scientific evidence and certification, he added.

Patanjali spokesperson S K Tijarawala said Coronil has done business of Rs 500 crore in the last seven months.

Coronil has been developed by Patanjali Research Institute. It had started work on an ayurvedic remedy for COVID-19 in January 2020.

Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.



Bengaluru, May 13: The Karnataka government on Thursday announced floating a global tender for procuring two crore COVID-19 vaccines owing to supply shortage.

Chief Minister B S Yediyurappa said a Task Force has been set up to oversee the preparation for a probable third wave of COVID-19.

"The state has placed a purchase order for three crore doses of vaccines, two crore doses of Covishield and one crore doses of Covaxin.

We are floating global tenders for an additional two crores," Yediyurappa told reporters here.

He was briefing them about the various measures initiated by his government to deal with the pandemic and improving the health infrastructure in the state.

On the occasion, he said the government was appointing Prof Kang as an adviser on vaccination strategy.

"She Prof Kang is a member of several advisory committees for the World Health Organisation (WHO), mainly related to research and the use of vaccines," he added.

According to Yediyurappa, so far 1.10 crore doses have been supplied by the Centre, of which 99.5 lakh are Covishield vaccines and 10.9 lakh are Covaxin.

He said that 14.87 lakh beneficiaries have completed 6 weeks after taking the first dose of Covishield vaccine and are eligible for second one, whereas 5.10 lakh beneficiaries have completed four weeks after taking the first dose of Covaxin.

Thus, a total of 19.97 lakh people are eligible for second dose as on today.

The state government had on Wednesday announced suspension of the vaccination drive for people between the age group of 18 and 44 years due to the shortage of vaccine.

It said the available stock will be utilised to vaccinate people who are due for second dose.

The Chief Minister also explained the various measures adopted since the outbreak of COVID in the state last year.

He claimed that the recent lockdown-like restrictions brought down the infections in the state from over 50,000 to less than 40,000 now.

To meet the increased oxygen requirement, the government decided to increase the supply of Liquid Medical Oxygen (LMO), massive scaling of localised generation capacity through oxygen generators and large scale procurement of concentrators and cylinders.